Metropolis Healthcare Ltd (METROPOLIS) is currently trading at 595.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Metropolis Healthcare Limited is a pan-India clinical diagnostics company operating a large hub-and-spoke laboratory network, offering routine to super-specialty tests, genomics, B2C and B2B services, preventive wellness (TruHealth) and institutional clinical research support across India and selected international markets. Q3 FY26 organic revenue grew 15% to INR 371 crore with EBITDA of INR 93 crore and margin expansion to 25%, while Group revenue grew 26% to INR 406 crore; PAT excluding exceptional items rose meaningfully, reflecting improving mix, productivity initiatives and economies of scale. Metropolis is actively premiumising revenue via TruHealth and specialty testing: TruHealth grew ~25% and now contributes 19% of organic revenue, while specialty contribution rose to ~38% driven by genomics, NGS test additions, clinician engagement and AI-enabled interpretation. Network scale and disciplined M&A are central: the company operates 219 labs and ~4,862 centres, added ~112 centres in Q3, completed four acquisitions (including Core Diagnostics) and launched a Centre of Genomics with Illumina partnership to capture higher-value testing demand. Financially conservative posture: Metropolis remains net debt-free with cash ~INR 127 crore, FY26 capex guidance of INR 55–60 crore focused on labs, IT and advanced equipment, and the Board approved a 3:1 bonus share proposal signalling confidence in liquidity and shareholder alignment.

Over the past 52 weeks, Metropolis Healthcare Ltd has traded between a low of ₹413.00 and a high of ₹608.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Metropolis Healthcare Ltd has a market capitalization of approximately 12,396.41. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Metropolis Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 61.12 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 12,396.41 Cr, Metropolis Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Metropolis Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Metropolis Healthcare Ltd is 61.12. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company scheduled a board meeting on August 04, 2026 to consider and approve the audited financial results for the quarter ended June 30, 2026.

The company has scheduled a board meeting on August 04, 2026 to consider and approve the audited financial results for the quarter ended June 30, 2026.

Revenue from operations rose 25.8% YoY to Rs 406 crore, and PAT increased 33.7% YoY to Rs 42 crore.

Metropolis said consolidated revenue rose 23% YoY in Q4FY26, led by traction in TruHealth wellness and specialised testing, with growth across both B2B and B2C channels.